Results 161 to 167 of about 6,775 (167)

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Blood, 2012
Randy Gascoyne, Laurie Sehn, Stewart Douglas A   +2 more
exaly  

OBINUTUZUMAB

2015
openaire   +1 more source

Obinutuzumab

Reactions Weekly, 2018
openaire   +2 more sources

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Advances in Therapy, 2016
Christian Klein, , Gunter Fingerle-Rowson   +2 more
exaly  

NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment

OncoImmunology, 2018
Cedric Menard, Franck Morschhauser, Martin Villalba   +2 more
exaly  

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy

CKJ: Clinical Kidney Journal
Wang Haiping
exaly  

Obinutuzumab

Reactions Weekly, 2017
openaire   +1 more source